Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 300-62-9
Drug Levels and Effects
Summary of Use during Lactation
In dosages prescribed for medical indications, some evidence indicates that amphetamine does not affect nursing infants adversely. The effect of amphetamine in milk on the neurological development of the infant has not been well studied. Large dosages of amphetamine might interfere with milk production, especially in women whose lactation is not well established. Therapeutic dosages of amphetamine can be used during nursing with monitoring of the infant for irritability, insomnia, and feeding difficulty.[1] Breastfeeding is generally discouraged in mothers who are actively abusing amphetamines.[2-4]
Drug Levels
Maternal Levels. A nursing woman was taking racemic amphetamine 5 mg orally 4 times daily at 10 am, noon, 2 pm and 4 pm for narcolepsy. Trough milk levels of 55 and 68 mcg/L were found before the 10 am dose on days 10 and 42 postpartum, respectively. Milk levels were 118 and 138 mcg/L before the 2 pm doses on days 10 and 42, respectively.[5]
A woman took 35 mg of amphetamine daily for narcolepsy and exclusively breastfed her infant for 6 months. Breastmilk samples were taken just before her morning dose at 2, 5 and 9 weeks postpartum. Breastmilk levels of amphetamine were 74, 82 and 82 mcg/L, respectively. These values represent a weight-adjusted dosage of 1.9% to 2.1% of the maternal dosage and an absolute infant dosage of 11.1 to 12.4 mcg/kg daily.[6]
Infant Levels. Amphetamine was measured in a 12-hour urine collection in a breastfed infant whose mother was taking racemic amphetamine 5 mg 4 times daily. The infant's urinary excretion of amphetamine ranged from 0.1 to 0.3% of the mother's urinary excretion.[5]
The infant of a mother who was taking amphetamine 35 mg daily for narcolepsy during pregnancy and postpartum was exclusively breastfed for 6 months. Infant blood samples were taken just before the mother's morning amphetamine dose at 2, 5 and 9 weeks postpartum. Infant serum concentrations at these times were 3.1, 2 and 1.4 mcg/L, respectively. These values represented 15%, 7% and 5% of simultaneous maternal serum concentrations.[6]
Effects in Breastfed Infants
One infant whose mother was being treated for narcolepsy with racemic amphetamine 5 mg 4 times daily was exposed to the drug in milk for the (unspecified) duration of breastfeeding. There were no signs of abnormal development during the first 2 years of life.[5]
The infant of a mother who was taking amphetamine 35 mg daily for narcolepsy during pregnancy and postpartum was exclusively breastfed for 6 months. The infant experienced no adverse reactions and grew normally.[6]
A prospective study followed 13 women who were taking an amphetamine (7 mixed racemic amphetamine salts [Adderal] and 6 lisdexamfetamine) during breastfeeding (9 exclusively). Median age of the child at the follow-up was 18 (IRQ 5.25 to 34) months. Adverse effects were reported among 5 children: somnolence in 1, crying or restlessness in 3, and colic or constipation in 4. All children were reported to have normal gross motor development, based on the Denver developmental scale. Neurodevelopment was also normal with median PEDsQL score of 97.16, psychosocial health score 99.33 and physical health score 98.75.[7]
Effects on Lactation and Breastmilk
In 2 papers by the same authors, 20 women with normal physiologic hyperprolactinemia were studied on days 2 or 3 postpartum. Eight received dextroamphetamine 7.5 mg intravenously, 6 received 15 mg intravenously and 6 who served as controls received intravenous saline. The 7.5 mg dose reduced serum prolactin by 25 to 32% compared to control, but the difference was not statistically significant. The 15 mg dose significantly decreased serum prolactin by 30 to 37% at times after the infusion. No assessment of milk production was presented.[8,9] The authors also quoted data from another study showing that a 20 mg oral dose of dextroamphetamine produced a sustained suppression of serum prolactin by 40% in postpartum women. The maternal prolactin level in a mother with established lactation may not affect her ability to breastfeed.
In a retrospective Australian study, mothers who used intravenous amphetamines during pregnancy were less likely to be breastfeeding their newborn infants at discharge than mothers who abused other drugs (27% vs 42%). The cause of this difference was not determined.[10]
A mother took amphetamine 35 mg daily for narcolepsy during pregnancy and postpartum. She exclusively breastfed her infant for 6 months with no evidence of an adverse effect on milk production.[6]
Alternate Drugs to Consider
(ADHD) Dextroamphetamine, Lisdexamfetamine, Methylphenidate (Narcolepsy) Armodafinil, Dextroamphetamine, Lisdexamfetamine, Methylphenidate, Modafinil, Oxybate Salts, Pitolisant
References
- 1.
- Scoten O, Tabi K, Paquette V, et al. Attention-deficit/hyperactivity disorder in pregnancy and the postpartum period. Am J Obstet Gynecol 2024;231:19-35 [PubMed: 38432409]
- 2.
- Oei JL, Kingsbury A, Dhawan A, et al. Amphetamines, the pregnant woman and her children: A review. J Perinatol 2012;32:737-47 [PubMed: 22652562]
- 3.
- AAP Section on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics 2012;129:e827-41 [PubMed: 22371471]
- 4.
- Wong S, Ordean A, Kahan M. SOGC clinical practice guidelines: Substance use in pregnancy: No. 256, April 2011. Int J Gynaecol Obstet 2011;114:190-202 [PubMed: 21870360]
- 5.
- Steiner E, Villen T, Hallberg M, et al. Amphetamine secretion in breast milk. Eur J Clin Pharmacol 1984;27:123-4 [PubMed: 6489423]
- 6.
- Öhman I, Wikner BN, Beck O, et al. Narcolepsy treated with racemic amphetamine during pregnancy and breastfeeding. J Hum Lact 2015;31:374-6 [PubMed: 25948577]
- 7.
- Hazan A, Kaduri NB, De-Haan T, et al. I am a law student treated with amphetamines for attention deficit hyperactive disorder (ADHD): Can I breastfeed my child? A pilot study. Neurotoxicol Teratol 2023;98:15.doi:10.1016/j.ntt.2023.107219 [CrossRef]
- 8.
- DeLeo V, Cella SG, Camanni F, et al. Prolactin lowering effect of amphetamine in normoprolactinemic subjects and in physiological and pathological hyperprolactinemia. Horm Metab Res 1983;15:439-43 [PubMed: 6642414]
- 9.
- Petraglia F, De Leo V, Sardelli S, et al. Prolactin changes after administration of agonist and antagonist dopaminergic drugs in puerperal women. Gynecol Obstet Invest 1987;23:103-9 [PubMed: 3583091]
- 10.
- Oei J, Abdel-Latif ME, Clark R, et al. Short-term outcomes of mothers and infants exposed to antenatal amphetamines. Arch Dis Child Fetal Neonatal Ed 2010;95:F36-F41 [PubMed: 19679891]
Substance Identification
Substance Name
Amphetamine
CAS Registry Number
300-62-9
Drug Class
Breast Feeding
Lactation
Milk, Human
Adrenergic Agents
Central Nervous System Stimulants
Dopamine Agents
Sympathomimetics
Wakefulness-Promoting Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- PubMedLinks to PubMed
- NTP Toxicology and Carcinogenesis Studies of dl-Amphetamine Sulfate (CAS No. 60-13-9) in F344/N Rats and B6C3F1 Mice (Feed Studies).[Natl Toxicol Program Tech Rep ...]NTP Toxicology and Carcinogenesis Studies of dl-Amphetamine Sulfate (CAS No. 60-13-9) in F344/N Rats and B6C3F1 Mice (Feed Studies).National Toxicology Program. Natl Toxicol Program Tech Rep Ser. 1991 Jun; 387:1-185.
- Review Dextroamphetamine.[Drugs and Lactation Database (...]Review Dextroamphetamine.. Drugs and Lactation Database (LactMed®). 2006
- Review Lisdexamfetamine.[Drugs and Lactation Database (...]Review Lisdexamfetamine.. Drugs and Lactation Database (LactMed®). 2006
- Review Methamphetamine.[Drugs and Lactation Database (...]Review Methamphetamine.. Drugs and Lactation Database (LactMed®). 2006
- Review Methylphenidate.[Drugs and Lactation Database (...]Review Methylphenidate.. Drugs and Lactation Database (LactMed®). 2006
- Amphetamine - Drugs and Lactation Database (LactMed®)Amphetamine - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...